Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database - Top-Institutions - MDSpire

Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database

  • By

  • Connor Frey

  • Mahyar Etminan

  • Hannah Cherniawsky

  • April 10, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology/Oncology
    • Cellular Therapy
    • Immunotherapy

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology/Oncology
    • Cellular Therapy
    • Immunotherapy

  • #3

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology/Oncology
    • Cellular Therapy
    • Immunology

  • #4

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Hematology/Oncology
    • Cellular Therapy
    • Immunotherapy

  • #5

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Cancer Research
    • Immunotherapy
    • Pharmacovigilance

Original Source(s)

Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database

  • by Connor Frey, Mahyar Etminan, Hannah Cherniawsky

  • April 10, 2026

Related Content

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines

Dietary patterns among individuals with plasma cell disorders– opportunities for targeted interventions

Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature